| Dr Stephanie Joanne Ash, MD | |
|
829 N Pine Rd, Essexville, MI 48732 | |
| (989) 895-6484 | |
| (989) 895-2520 |
| Full Name | Dr Stephanie Joanne Ash |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 33 Years |
| Location | 829 N Pine Rd, Essexville, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043294457 | NPI | - | NPPES |
| 0983575 | Other | MI | HEALTH PLUS |
| 1020872 | Other | MI | HEALTH ADVANTAGE |
| 1020872 | Other | MI | MCLAREN HEALTH PLAN |
| 1600910771 | Other | MI | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 4301067456 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Bay Region | Bay city, MI | Hospital |
| Covenant Medical Center | Saginaw, MI | Hospital |
| Entity Name | Stephanie J Ash Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972617835 PECOS PAC ID: 8820094956 Enrollment ID: O20061013000161 |
News Archive
Impax Laboratories, Inc. confirms that it has initiated a challenge of the patents listed by Galderma Laboratories, L.P. in connection with its ORACEA® (doxycycline) delayed-release capsules, 40 mg.
Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer.
An innovative treatment technology could give cancer patients new hope for survival. In an international study based at Lawson Health Research Institute and London Health Sciences Centre's London Regional Cancer Program (LRCP), scientists are testing a therapy with the potential to eradicate cancers previously thought to be incurable.
Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephanie Joanne Ash, MD 829 N Pine Rd, Essexville, MI 48732-2109 Ph: (989) 895-6484 | Dr Stephanie Joanne Ash, MD 829 N Pine Rd, Essexville, MI 48732 Ph: (989) 895-6484 |
News Archive
Impax Laboratories, Inc. confirms that it has initiated a challenge of the patents listed by Galderma Laboratories, L.P. in connection with its ORACEA® (doxycycline) delayed-release capsules, 40 mg.
Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer.
An innovative treatment technology could give cancer patients new hope for survival. In an international study based at Lawson Health Research Institute and London Health Sciences Centre's London Regional Cancer Program (LRCP), scientists are testing a therapy with the potential to eradicate cancers previously thought to be incurable.
Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.
› Verified 3 days ago